In conclusion, individualised retreatment with intravenous ofatumumab, at a dose of 700 mg X 2 infusions, was efficacious and generally safe in active RA patients with no major differences observed across trials recruiting either biologic-naive, DMARDs-refractory, or patients previously exposed to TNF-inhibitors. Here, TNF is linked to rheumatoid arthritis.